# GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

> **NCT06546384** · NA · NOT_YET_RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 64 (estimated)

## Conditions studied

- Adiposity
- Fatty Liver
- Alcohol Use Disorder

## Interventions

- **DRUG:** Semaglutide
- **BEHAVIORAL:** Weight reduction recommendations (nutritional and exercise)

## Key facts

- **NCT ID:** NCT06546384
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-04-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06546384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06546384, "GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06546384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*